Online inquiry

IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ8323MR)

This product GTTS-WQ8323MR is a type of mRNA modified with 5-Methoxy-UTP, which ecodes the monoclonal antibody that targets TFRC gene. The antibody can be applied in Glioblastoma research.

Specifications
Product type	mRNA
Modified bases	5-Methoxy-UTP
5' Cap	Cap 0
Species	Corynebacterium diphtheriae; Homo sapiens
RefSeq	NM_001128148.3
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	7037
UniProt ID	P02786

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ8323MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ4455MR	IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	BMS-901608
GTTS-WQ9588MR	IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	JNJ-61610588
GTTS-WQ11048MR	IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	MCLA-128
GTTS-WQ2903MR	IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	AMG827
GTTS-WQ11540MR	IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	MGA031
GTTS-WQ2774MR	IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	AMG-282
GTTS-WQ6449MR	IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	CT-P23
GTTS-WQ4483MR	IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	BMS-931699

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST